Navigation Links
S&P Equity Research Picks COV Focus Stock of the Week
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Covidien Plc (COV: $53) has been picked by Standard & Poor's Equity Research as its Focus Stock of the Week.  COV carries S&P's highest investment recommendation of 5-STARS, or Strong Buy.  Covidien is one of the largest suppliers in the world of certain medical devices, specialty pharmaceuticals and medical supplies, and is number-one or number-two in businesses representing more than 75% of its sales.  The medical devices segment, the company's fastest growing segment, accounts for about two-thirds of its annual revenues.

"We believe Covidien has improved its top-line growth prospects through portfolio optimization," said Phillip Seligman, Healthcare Analyst at Standard & Poor's Equity Research.  "Since its formation when Tyco International was split into three companies in July 2007, it has completed 12 acquisitions, 10 licensing agreements, and eight divestitures of underperforming businesses."

Seligman noted that while U.S. and European procedure volume growth has been tepid, Covidien's mix shift has enabled it to increasingly penetrate the hospital markets.  "Other growth drivers we see include accelerated new product launches, sales force expansion, and increasing penetration of emerging markets," added Seligman.  "Long term, we expect volume trends to benefit from the aging U.S. and rest-of-world populations and improving living standards in emerging markets."

To view a video of Mr. Seligman discussing COV, paste the following link into your browser.

http://link.delvenetworks.com/media/?mediaId=d660d4ef8a4e4907a956ac13cb5e267e&width=480&height=411&playerForm=DelvePlayer&autoplay=true

About Standard & Poor's Equity Research Services

As one of the world's largest producers of independent equity research, Standard & Poor's licenses its research to global institutions for their investors and advisors.  Standard & Poor's team of experienced U.S., European and Asian equity analysts use a fundamental, bottom-up approach to assess a global universe of equities across industries worldwide.  Follow Standard & Poor's equity analysts' U.S. market commentary each day at http://www.equityresearch.standardandpoors.com/.

Standard & Poor's keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of Standard & Poor's may have information that is not available to other Standard & Poor's business units. Standard & Poor's has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. Standard & Poor's does not trade for its own account.  The analytical and ethical conduct of Standard & Poor's equity analysts is governed by the firm's Research Objectivity Policy, a copy of which may also be found at www.standardandpoors.com or by clicking here.

All information provided by Standard & Poor's is impersonal and not tailored to the needs of any person, entity or group of persons.  Past performance is no indication of future results. Standard & Poor's and its affiliates provide a wide range of services to, or relating to, many organizations, including issuers of securities, investment advisers, broker-dealers, investment banks, other financial institutions and financial intermediaries, and accordingly may receive fees or other economic benefits from those organizations, including organizations whose securities or services they may recommend, rate, include in model portfolios, evaluate or otherwise address.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you nor is it considered to be investment advice. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

This material is based upon information that we consider to be reliable, but neither S&P nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. With respect to reports issued to clients in Japan and in the case of inconsistencies between the English and Japanese version of a report, the English version prevails. With respect to reports issued to clients in German and in the case of inconsistencies between the English and German version of a report, the English version prevails. Neither S&P nor its affiliates guarantee the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Neither S&P nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.


'/>"/>
SOURCE Standard & Poor's
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S&P Equity Research Issues Health Care Sector Predictions for 2011
2. Warner Chilcott Prices Secondary Equity Offering
3. Warner Chilcott Announces Secondary Equity Offering
4. TechniScan Secures $10 Million Equity Financing Facility
5. Rockbridge Growth Equity Leads Acquisition of Connect America, a Leading Direct to Consumer Provider of Personal Emergency Response Systems (PERS)
6. Gliknik Announces Completion of Equity Financing
7. Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group
8. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
9. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
10. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
11. InfraReDx Completes $21 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):